Valliance Asset Management’s LakeShore Biopharma Warrants LSBPW Stock Holding History

Valliance Asset Management’s Portfolio LSBPW Stock Details LSBPW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-750,000	Closed	-$29.9K	–	6
2025 Q2	$29.9K	Hold	750,000	–	–	0.24%	5
2025 Q1	$30.9K	Hold	750,000	–	–	0.07%	25
2024 Q4	$59.5K	Hold	750,000	–	–	0.11%	18
2024 Q3	$49.6K	Hold	750,000	–	–	0.06%	7
2024 Q2	$66K	Hold	750,000	–	–	0.1%	15
2024 Q1	$53.7K	Hold	750,000	–	–	0.13%	8
2023 Q4	$28.5K	Hold	750,000	–	–	1.01%	5
2023 Q3	$30.9K	Hold	750,000	–	–	0.11%	13
2023 Q2	$35.3K	Hold	750,000	–	–	0.56%	3
2023 Q1	$117K	Buy	+750,000	New	+$114K	0.21%	8

Other funds holding LSBPW

HIM

HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.78% 1-Year Est. Return

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

Valliance Asset Management's LSBPW Position: Q3 2025 in Review

Valliance Asset Management sold out of LakeShore Biopharma Warrants (LSBPW) in Q3 2025, closing a stake of 750,000 shares — an estimated $29.9K sold.

Valliance Asset Management first reported a position in LSBPW in Q1 2023 and held it in 10 quarters. The position peaked at $117K in Q1 2023. 3 funds tracked by Wall St. Rank hold LSBPW as of Q3 2025.

Valliance Asset Management reported no remaining LakeShore Biopharma Warrants position as of Q3 2025 after selling out during the quarter.
Valliance Asset Management sold 750,000 LakeShore Biopharma Warrants shares in Q3 2025, an estimated $29.9K.
Valliance Asset Management first reported a position in LakeShore Biopharma Warrants in Q1 2023 and held it in 10 quarters.
Valliance Asset Management's LakeShore Biopharma Warrants position peaked at $117K in Q1 2023.
3 funds tracked by Wall St. Rank held LakeShore Biopharma Warrants as of Q3 2025.

Based on Valliance Asset Management's 13F filing for Q3 2025, filed 22 Oct 2025.